T-cell malignancies following CAR T-Cell therapy: insights from the FDA Adverse Event Reporting System (FAERS)

Axicabtagene ciloleucel and tisagenlecleucel may be associated with a higher reporting frequency of T-cell lymphoma than other drugs.